Kosan BioSciences -- KOSN Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Kosan BioSciences -- KOSN

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: quidditch who wrote (459)	6/22/2004 4:22:25 PM
From: keokalani'nui	Read Replies (1) of 933

The ticker told the story. Roche, Kosan to end colorectal cancer drug study Tuesday June 22, 4:18 pm ET CHICAGO, June 22 (Reuters) - Roche (ROG.VX) and Kosan Biosciences Inc. (NasdaqNM:KOSN - News) on Tuesday said they plan to halt a human clinical trial for an investigational drug to treat colorectal cancer, blaming a toxic build-up of the drug. The companies, which are co-developing the experimental compound, said they will continue to study the drug, called KOS-862, for prostate cancer, citing high response rates in early studies for that disease.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next